Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Adaptimmune Therapeutics PLC | 4,901,310 | reported | 06 Jun 2018 | tx 13+3,312,797−1,248,067 |
| Sionna Therapeutics, Inc. | 2,671,721 | reported | 27 May 2026 | tx 18+3,724,918−5,077,021 |
| ProNAi Therapeutics Inc | 1,989,949 | reported | 21 Jul 2015 | tx 4+1,989,949−1,725,790 |
| Edgewise Therapeutics, Inc. | 30,000 | reported | 16 Jun 2025 | tx 18+15,050,751 |
Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 11 buys in history.
| ARS Pharmaceuticals, Inc. | 30,000 | reported | 25 Jun 2025 | tx 20+8,883,512−26,987,057 |
| PMV Pharmaceuticals, Inc. | 16,333 | reported | 02 Jun 2022 | tx 13+7,080,663−6,114,330 |
| Janux Therapeutics, Inc. | 12,500 | reported | 14 Jun 2022 | tx 16+3,085,264−2,377,387 |
| Anthera Pharmaceuticals Inc | 12,000 | reported | 08 May 2012 | tx 3+49,000 |
| Decibel Therapeutics, Inc. | 10,000 | reported | 17 Jun 2022 | tx 10+4,975,192−17,376,193 |
| Nivalis Therapeutics, Inc. | 0 | reported | 20 May 2024 | tx 30+5,040,194−5,040,194 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 27 May 2026 | SALE | Sionna Therapeutics, Inc. | 101 | 44.49 USD | 10b5-1 |
| 07 May 2026 | SALE | Sionna Therapeutics, Inc. | 48,546 | 44.61 USD | 10b5-1 |
| 08 May 2026 | SALE | Sionna Therapeutics, Inc. | 59,767 | 44.58 USD | 10b5-1 |
| 11 May 2026 | SALE | Sionna Therapeutics, Inc. | 184,639 | 46.22 USD | 10b5-1 |
| 02 Feb 2026 | SALE | Sionna Therapeutics, Inc. | 1,890 | 44.57 USD | |
| 03 Feb 2026 | SALE | Sionna Therapeutics, Inc. | 29,063 | 44.58 USD | |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 30,000 | 15.00 USD | |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 15,000 | 9.70 USD | |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 15,000 | 12.50 USD | |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 15,000 | 3.61 USD | |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 15,000 | 2.00 USD | |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 15,000 | 3.27 USD | |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 15,000 | 2.12 USD | |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 15,000 | 2.60 USD | |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 15,000 | 0.99 USD | |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 15,000 | 0.97 USD | |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 15,000 | 2.49 USD | |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 15,000 | 1.64 USD | |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 15,000 | 2.74 USD | |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 15,000 | 0.00 USD | deriv |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 15,000 | 0.00 USD | deriv |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 15,000 | 0.00 USD | deriv |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 15,000 | 0.00 USD | deriv |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 15,000 | 0.00 USD | deriv |
| 28 Jan 2026 | EXERCISE | Corvus Pharmaceuticals, Inc. | 15,000 | 0.00 USD | deriv |
1 purchase reported after at least 12 months of silence — most recent on 25 Sept 2020.